Prosecution Insights
Prosecution Insights
Tech Center 1700 • Art Units: 1638 1759
This examiner grants 46% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18749358 | DIFFERENTIATION AND USE OF HUMAN MICROGLIA-LIKE CELLS FROM PLURIPOTENT STEM CELLS AND HEMATOPOIETIC PROGENITORS | Non-Final OA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 17629348 | METHODS AND COMPOSITIONS FOR SEXING AND STERILIZATION IN DROSOPHILA SUZUKII AND AEDES AEGYPTI | Non-Final OA | The Regents of the University of California |
| 17051089 | De Novo Formation of the Biliary System by Hepatocyte Transdifferentiation | Final Rejection | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 16489338 | DIFFERENTIATION AND USE OF HUMAN MICROGLIA-LIKE CELLS FROM PLURIPOTENT STEM CELLS AND HEMATOPOIETIC PROGENITORS | Final Rejection | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 18167517 | COMPOSITIONS AND METHODS FOR SCREENING 4R TAU TARGETING AGENTS | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 18211692 | REPLICATION-COMPETENT VESICULAR STOMATITIS VIRUSES | Non-Final OA | Mayo Foundation for Medical Education and Research |
| 17913477 | NON-VIRAL DNA VECTORS AND USES THEREOF FOR EXPRESSING FACTOR IX THERAPEUTICS | Non-Final OA | Generation Bio Co. |
| 17624347 | PRIMING MEDIA AND METHODS FOR STEM CELL CULTURE AND THERAPY | Non-Final OA | Case Western Reserve University |
| 17600799 | METHODS AND COMPOSITIONS FOR CELL THERAPY | Non-Final OA | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. |
| 17825950 | STEM CELL IMPREGNATED CORTICAL FIBERS | Non-Final OA | Zavation Medical Products, LLC |
| 17796334 | DNA Amplification Method | Non-Final OA | Oxford University Innovation Limited |
| 18890594 | COMPOSITIONS AND METHODS FOR THERAPEUTIC DELIVERY | Non-Final OA | GenVivo, Inc. |
| 17604916 | TREHALOSE-CONTAINING LIQUID FOR MAMMALIAN CELL PRESERVATION | Non-Final OA | OTSUKA PHARMACEUTICAL FACTORY, INC. |
| 17276983 | COMPOSITIONS AND METHODS FOR DELIVERY OF NUCLEIC ACIDS | Non-Final OA | ModernaTX, Inc. |
| 17625290 | DIFFERENTIAL KNOCKOUT OF A HETEROZYGOUS ALLELE OF RPE65 | Final Rejection | EmendoBio Inc. |
| 17865881 | Therapeutic Monocytic Lineage Cells | Non-Final OA | CREATIVE MEDICAL TECHNOLOGIES, INC. |
| 18265820 | LENTIVIRUS VECTOR WITH CONTROLLABLE EXPRESSION OF GENE OF INTEREST, AND PACKAGING METHOD THEREFOR | Non-Final OA | OBIO TECHNOLOGY (SHANGHAI) CORP., LTD. |
| 17731616 | PRESERVATION METHODS USING TREHALOSE WITH OTHER CRYOPROTECTANTS BEING ABSENT FROM THE CRYOPRESERVATION PROTOCOL | Non-Final OA | LifeNet Health |
| 17604360 | CYBB LENTIVIRAL VECTOR, LENTIVIRAL VECTOR-TRANSDUCED STEM CELL, AND PREPARATION METHOD AND APPLICATION THEREOF | Final Rejection | BEIJING MEIKANG GENO-IMMUNE BIOTECHNOLOGY CO., LTD. |
| 17601542 | The Treatment of Protein Aggregation Diseases | Final Rejection | Pharmakure Limited |
| 17600480 | OPERATION PROCESS FOR A CELL CULTIVATION SYSTEM | Non-Final OA | THE AUTOMATION PARTNERSHIP (CAMBRIDGE ) LTD. |
| 17056368 | SPLICE MODULATING OLIGONUCLEOTIDES TARGETING RECEPTOR FOR ADVANCED GLYCATION END PRODUCTS AND METHODS OF USE | Non-Final OA | LifeSplice Pharma LLC |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy